Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
IPO Year: 2018
Exchange: NYSE
Website: arcusbio.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/18/2022 | $33.00 | Neutral | BofA Securities |
10/11/2022 | $40.00 | Overweight | Morgan Stanley |
11/19/2021 | $42.00 → $53.00 | Buy | Citigroup |
11/19/2021 | $48.00 → $60.00 | Overweight | Barclays |
11/18/2021 | $68.00 → $100.00 | Outperform | SVB Leerink |
11/9/2021 | $45.00 → $48.00 | Overweight | Barclays |
10/15/2021 | $57.00 | Buy | BTIG Research |
8/6/2021 | $63.00 → $68.00 | Outperform | SVB Leerink |
6/24/2021 | $53.00 → $63.00 | Outperform | SVB Leerink |
Data from the casdatifan 100 mg expansion cohort of ARC-20, a Phase 1/1b study in clear cell renal cell carcinoma (ccRCC), are expected to be presented at a medical conference in the fourth quarter of 2024 PEAK-1, the initial Phase 3 study evaluating casdatifan in combination with cabozantinib, is expected to begin in the first half of 2025 Patient enrollment has completed for the Phase 3 study STAR-221 (upper gastrointestinal (GI) cancers) for domvanalimab plus zimberelimab and chemotherapy Arcus is well-positioned to advance its full pipeline with $1.0 billion in cash, cash equivalents and marketable securities and runway into 2027 Conference call today at 2:00 PM PT / 5:00 P
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Thursday, August 8th, 2024 at 2 PM PT / 5 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended June 30th, 2024. Investors interested in listening to the conference call may do so by dialing (404) 975-4839 (local) or (833) 470-1428 (toll-free), using Access Code: 287576. To access the live webcast and accompanying slide presentation, please visit the "Investors & Media" section of the Arcu
Arcus data will be disclosed in two oral presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Updated data, including median progression-free survival (PFS), from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper GI cancers Data, including overall survival (OS) and PFS, from ARC-9 evaluating an etrumadenant plus zimberelimab-based treatment combination in third-line metastatic colorectal cancer Data from the casdatifan 100 mg expansion cohort of ARC-20, a Phase 1/1b study of casdatifan in clear cell renal cell carcinoma (ccRCC), are expected to be presented in the second half of 2024 Completion of enrollment fo
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Wednesday, May 8th, 2024 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended March 31st, 2024. Investors interested in listening to the conference call may do so by dialing (404) 975-4839 (local) or (833) 470-1428 (toll-free), using Access Code: 034427. To access the live webcast and accompanying slide presentation, please visit the "Investors & Media" section of the
Arcus and Gilead announced an additional equity investment of $320 million into Arcus and modifications to their domvanalimab + zimberelimab clinical program to focus on the highest unmet medical needs and largest market opportunities Pharmacokinetic (PK), pharmacodynamic (PD), safety and early efficacy data, including initial observations from the expansion cohort, from ARC-20, support potential for casdatifan (AB521) to result in greater HIF-2a inhibition than the marketed competitor; expansion cohort data expected to be presented in the second half of 2024 Multiple datasets expected to be presented in the first half of 2024 including EDGE-Gastric for domvanalimab + zimberelimab +
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Wednesday, February 21, 2024 at 2:00 PM PT / 5:00 PM ET to discuss pipeline updates and details of the Company's financial results for the quarter and year ended December 31st, 2023. Investors interested in listening to the conference call may do so by dialing (404) 975-4839 (local) or (833) 470-1428 (toll-free), using Access Code: 235272. To access the live webcast and accompanying slide presentation, please visit the "Investors & Medi
Data from the A1 cohort of EDGE-Gastric, the Phase 2 study of domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, in first-line upper gastrointestinal cancers will be presented at the virtual ASCO Monthly Plenary Series by Yelena Y. Janjigian, M.D., Chief Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center on November 7, 2023 Arcus Biosciences will also report third quarter 2023 results and host a conference call aftermarket on November 7, 2023 Arcus Biosciences, Inc. (NYSE:RCUS) today announced that data from cohort A1 of the ongoing Phase 2 EDGE-Gastric study will be presented at the American Society of Clinical Oncology (ASCO) Monthly Plenary Series on Novembe
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced it will report financial results and key pipeline updates for the first quarter ended March 31, 2022 after the U.S. markets close on Monday, May 9, 2022. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well
SALT LAKE CITY, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the promotion of Nicole Lambert to chief operating officer (COO). In her new role, she will continue to report directly to Paul J. Diaz, president and CEO, Myriad Genetics. Over a 20-year career at the company, Lambert served in several senior leadership positions, most recently overseeing Myriad's Oncology, Women's Health and International business units as well as genetic testing laboratory operations. As COO, she assumes additional responsibility for accelerating the company's transformation and growth plans, elevating products to t
-- Gilead Exercises Options to Arcus's Anti-TIGIT Program (Domvanalimab and AB308), Etrumadenant (A2a/A2b Adenosine Receptor Antagonist) and Quemliclustat (Small Molecule CD73 Inhibitor) -- -- Arcus to Receive Option Payments Totaling $725 million -- -- Arcus will Host a Webcast Today, Thursday, November 18, 2021, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time -- Gilead Sciences, Inc. (NASDAQ:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced that Gilead has exercised its options to three programs in Arcus's clinical-stage portfolio, including both anti-TIGIT molecules, domvanalimab and AB308, as well as etrumadenant and quemliclustat. The companies also added a research c
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
BofA Securities initiated coverage of Arcus Biosciences with a rating of Neutral and set a new price target of $33.00
Morgan Stanley initiated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $40.00
Citigroup reiterated coverage of Arcus Biosciences with a rating of Buy and set a new price target of $53.00 from $42.00 previously
Barclays reiterated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $60.00 from $48.00 previously
SVB Leerink reiterated coverage of Arcus Biosciences with a rating of Outperform and set a new price target of $100.00 from $68.00 previously
Barclays reiterated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $48.00 from $45.00 previously
BTIG Research resumed coverage of Arcus Biosciences with a rating of Buy and set a new price target of $57.00
SVB Leerink reiterated coverage of Arcus Biosciences with a rating of Outperform and set a new price target of $68.00 from $63.00 previously
SVB Leerink reiterated coverage of Arcus Biosciences with a rating of Outperform and set a new price target of $63.00 from $53.00 previously
SVB Leerink reiterated coverage of Arcus Biosciences with a rating of Outperform and set a new price target of $53.00 from $54.00 previously
8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
10-Q - Arcus Biosciences, Inc. (0001724521) (Filer)
8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
10-Q - Arcus Biosciences, Inc. (0001724521) (Filer)
8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
ARS - Arcus Biosciences, Inc. (0001724521) (Filer)
DEFA14A - Arcus Biosciences, Inc. (0001724521) (Filer)
SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13G - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13G - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13G - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)
Facility adds operational flexibility and provides funding for the recently announced Phase 3 PEAK-1 study for casdatifan. $150 million committed, of which $50 million was drawn at closing and the remaining $100 million available at Arcus's sole discretion. Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported it has obtained a $250 million term loan facility from Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in life sciences and technology-related markets. The additional capital strengthens Arcus's
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 21,100 shares of the Company's common stock at an exercise price per share of $18.01, which was the closing price on August 23, 2024, and restricted stock units to acquire a total of 10,550 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in Januar
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference Date: Wednesday, September 4th, 2024 at 4:55 p.m. ET Location: New York, NY Format: Fireside Chat Cantor Fitzgerald Global Healthcare Conference 2024 Date: Thursday, September 19th, 2024 at 10:55 a.m. ET Location: New York, NY Format: Fireside Chat Live webcasts of the fireside chats and panel will be available by visiting the "Investors & Med
Data from the casdatifan 100 mg expansion cohort of ARC-20, a Phase 1/1b study in clear cell renal cell carcinoma (ccRCC), are expected to be presented at a medical conference in the fourth quarter of 2024 PEAK-1, the initial Phase 3 study evaluating casdatifan in combination with cabozantinib, is expected to begin in the first half of 2025 Patient enrollment has completed for the Phase 3 study STAR-221 (upper gastrointestinal (GI) cancers) for domvanalimab plus zimberelimab and chemotherapy Arcus is well-positioned to advance its full pipeline with $1.0 billion in cash, cash equivalents and marketable securities and runway into 2027 Conference call today at 2:00 PM PT / 5:00 P
SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, to the board of directors of the Company, effective August 1, 2024. "We are thrilled to welcome Anne and Jennifer to our board as we prepare to start our Phase 3 clinical development of denifanstat in MASH this year," said Dave Happel, CEO of Sagimet. "Their expertise will be critical as we advance denifanstat into late-
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Thursday, August 8th, 2024 at 2 PM PT / 5 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended June 30th, 2024. Investors interested in listening to the conference call may do so by dialing (404) 975-4839 (local) or (833) 470-1428 (toll-free), using Access Code: 287576. To access the live webcast and accompanying slide presentation, please visit the "Investors & Media" section of the Arcu
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted six new employees options to purchase a total of 25,200 shares of the Company's common stock at an exercise price per share of $13.84, which was the closing price on July 8, 2024, and restricted stock units to acquire a total of 12,600 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 202
Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. ("Taiho") today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), an investigational small molecule CD73 inhibitor, in Japan and certain other territories in Asia (excluding mainland China). This option exercise is based on an option and license agreement between Taiho and Arcus contracted in September 2017. This is the fourth option exercise by Taiho to an Arcus program. In exchange for the exclusive license of quemliclustat, Taiho will make an option exercise payment, as well as additional payments upon achievement of clinical, regulatory and com
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 3,500 shares of the Company's common stock at an exercise price per share of $16.41, which was the closing price on June 24, 2024, and restricted stock units to acquire a total of 1,750 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted six new employees options to purchase a total of 36,100 shares of the Company's common stock at an exercise price per share of $16.09, which was the closing price on June 10, 2024, and restricted stock units to acquire a total of 18,050 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 20
This option exercise is based on an option and license agreement between Taiho and Arcus contracted in September 2017. This is the fourth option exercise by Taiho to an Arcus program. In exchange for the exclusive license of quemliclustat, Taiho will make an option exercise payment, as well as additional payments upon achievement of clinical, regulatory and commercialization milestones, and, if any products from the program are approved, will pay royalties on net sales of such products.
Arcus Biosciences (NYSE:RCUS) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Arcus Biosciences, presenting an average target of $34.25, a high estimate of $44.00, and a low estimate of $25.00. Observing a downward
Barclays analyst Peter Lawson maintains Arcus Biosciences (NYSE:RCUS) with a Overweight and lowers the price target from $35 to $25.
Cantor Fitzgerald analyst Alethia Young reiterates Arcus Biosciences (NYSE:RCUS) with a Overweight.
Truist Securities analyst Asthika Goonewardene maintains Arcus Biosciences (NYSE:RCUS) with a Buy and lowers the price target from $50 to $44.
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient populationArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced the completion of patient enrollment for STAR-221, a Phase 3 study in collaboration with Gilead Sciences, evaluating the combination of the Fc-silent anti-TIGIT antibody domvanalimab plus the anti-PD-1 monoclonal antibody zimberelimab and chemotherapy in patients with locally advanced unresectable or metastatic gastric, gastr
On Saturday, Gilead Sciences Inc (NASDAQ:GILD) and Arcus Biosciences Inc (NYSE:RCUS) released longer-term efficacy and safety results from Arm A1 of the Phase 2 EDGE-Gastric study. The updated data show consistent objective response rate (ORR) and provide mature progression-free survival (PFS) in patients with a locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma (upper GI cancers). Related: Gilead’s Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer. The ongoing, multi-arm, global Phase 2 EDGE-Gastric study is evaluating the safety and efficacy of various combinations of the Fc-silen
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $36 to $38.
Gilead Sciences, Inc. (NASDAQ:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual A2a/b adenosine receptor antagonist, plus anti-PD-1 monoclonal antibody zimberelimab, FOLFOX chemotherapy and bevacizumab (EZFB) in third-line metastatic colorectal cancer (mCRC). These results will be presented today during an oral session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by Zev A. Wainberg, M.D., MSc, Co-Director of the GI Oncology Program at University of California Los Angeles and a principal investigator of the ARC-9 trial (Abstract 3508). In Cohor
Gainers Cue Health (NASDAQ:HLTH) shares moved upwards by 42.1% to $0.13 during Friday's pre-market session. The company's market cap stands at $21.3 million. Innovative Eyewear (NASDAQ:LUCY) stock rose 24.73% to $0.23. The market value of their outstanding shares is at $4.0 million. SCWorx (NASDAQ:WORX) shares increased by 17.02% to $2.2. The company's market cap stands at $2.6 million. Arcus Biosciences (NYSE:RCUS) stock rose 16.33% to $18.94. The company's market cap stands at $1.7 billion. Biora Therapeutics (NASDAQ:BIOR) stock moved upwards by 15.01% to $0.57. The market value of their outstanding shares is at $20.5 million. Jin Medical International (NASDAQ:ZJYL) shares moved upwa
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Dimitry S.A. Nuyten, M.D., Ph.D, the Compensation Committee of the Company's Board of Directors granted Dr. Nuyten an option to purchase 170,000 shares of the Company's common stock at an exercise price per share of $26.00, which was the closing price on August 23, 2022, and restricted stock units to acquire a total of 42,500 shares of the Company's common stock. In addition to the awards to Dr. Nuyten, the Compensation Committee granted fifteen other new emplo
Dr. Nuyten will oversee Arcus's clinical development organization that includes nearly 200 employees and six clinical-stage programs targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b), HIF-2a and PD-1 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Dimitry S.A. Nuyten, M.D., Ph.D has been appointed chief medical officer (CMO) effective August 1, 2022. In his role as CMO, Dr. Nuyten will oversee Arcus's clinical development organization that includes nearly 200 employees and six clinical-stage programs targeting TIGIT, the a
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 31,600 shares of the Company’s common stock at an exercise price per share of $30.83, which was the closing price on January 8, 2021. The stock options were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08. About Arcu
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Andrew Perlman, M.D., Ph.D. and Michael Quigley, Ph.D. have joined the Company’s Board of Directors. Dr. Perlman will also serve as a member of Arcus’s Nominating and Corporate Governance Committee. Drs. Perlman and Quigley both have outstanding track records of success working in innovative and intensely competitive drug discovery and development organizations, including in the fields of oncology and immuno-oncology. “As we head into a pivotal year for Arcus that will include multiple randomize